What should you gather before handing a Health Canada medical device licence application to a consultant?
If you are the founder, first Regulatory Affairs / Quality Assurance (RA/QA) hire, or regulatory correspondent preparing a Canadian market-entry handoff, the most useful package is not a slide deck. It is a dated, source-backed application brief that already contains the intended purpose, candidate Class II / III / IV clues, candidate application-type notes, Regulatory Enrolment Process (REP) setup status, a similar-device table from the Medical Devices Active Licence Listing (MDALL), a class-linked evidence checklist, and the current Health Canada fee references. That package does not determine Health Canada class, licence outcome, compliance status, product safety, effectiveness, inspection outcome, or legal obligations. It gives your qualified RA/QA reviewer or consultant the minimum official-source starting point needed to spend paid time on judgment instead of re-collecting public inputs.
Next weekday publishing slot: May 28, 2026. Target query: what to gather before Health Canada medical device licence application consultant handoff.
This is not regulatory, legal, or compliance advice. TrueMedDevice does not determine Health Canada class, Medical Device Licence (MDL) applicability, Medical Device Establishment Licence (MDEL) applicability, submission pathway, substantial equivalence, reportability, complaint disposition, corrective and preventive action need, file closure, risk acceptability, compliance status, product safety, effectiveness, licence outcome, inspection outcome, or legal obligations. We organize source-backed evidence for qualified RA/QA professionals or consultants to review.
Pre-production brief
Role
Founder, first RA/QA lead, or regulatory correspondent at an early-stage medical device manufacturer planning a Canadian market-entry handoff.
Scenario
You have a product definition and know you need external review, but you do not want the first consultant call wasted on basic source collection.
Concrete problem
The team has partial facts scattered across labels, decks, old design files, and public licence searches, but no single official-source package that shows what is known, what is missing, and what should be escalated to qualified review.
Available inputs
Product name, draft intended purpose, label or instructions for use, manufacturer identity, any known device identifiers, existing comparator ideas, and the target country of sale.
Useful output
- •A one-screen consultant handoff brief with the product description, intended purpose, and open questions.
- •A source ledger that lets the next reviewer re-open every official page without redoing the search.
- •A gap list split into 'can hand off now' versus 'needs evidence before filing'.
TrueMedDevice role
- •Organize official Health Canada and public-source evidence into a dated briefing pack.
- •Turn scattered public records into candidate review points and evidence gaps.
- •Leave all regulatory, quality, legal, and safety decisions with qualified reviewers.
The official-source handoff workflow
1. Lock the intended purpose before you search
Health Canada's application guidance starts from the device description and intended use. Before you search MDALL, gather a clean intended-purpose statement, the latest instructions for use, and the label name you expect to appear in the application. If those inputs are still moving, your class clues and comparator clues will move with them.
2. Capture candidate class and application-type clues
Use Schedule 1 rules and comparable licensed products to create candidate class notes, not a final class claim. Then read Health Canada's application-type guidance to decide whether the handoff looks like a single device, medical device family, group, group family, system, or test kit. Health Canada explicitly tells manufacturers to document the structure rationale in the cover letter, so that rationale belongs in the handoff package.
3. Confirm Regulatory Enrolment Process readiness
The application implementation guidance says submissions go through the Regulatory Enrolment Process and that company enrolment must be completed before the licence application is filed. A practical consultant handoff should therefore note whether the company record, contact IDs, finance contact, and regulatory correspondent details already exist or still need setup.
4. Match evidence expectations to the likely class
Health Canada's current clinical-evidence guidance distinguishes the evidence burden by class. Class II manufacturers attest that they hold objective evidence. Class III manufacturers submit study summaries. Class IV manufacturers submit clinical data relied on for safety and effectiveness. The International Medical Device Regulators Forum (IMDRF) table-of-contents guidance adds that Class II uses a narrower content subset than Class III and IV. Your handoff should show which evidence bucket the product likely falls into and which pieces are still missing.
5. Put the current fee picture in front of the reviewer
As of April 1, 2026, Health Canada's published review-fee table lists C$643 for Class II applications, C$14,163 for Class III, and C$30,713 for Class IV. Separately, the published annual right-to-sell fee for licensed or authorized Class II, III, and IV devices is C$460. That does not tell you what class your device is. It does tell you that budget conversations should distinguish between filing fees and ongoing right-to-sell costs.
6. End the handoff with explicit gaps and boundary language
The most useful last page is a gap list: what is ready now, what still needs evidence, what needs judgment from qualified RA/QA or a consultant, and what assumptions remain unverified. That keeps the package operationally useful without implying that the public-source pass already resolved the regulatory decision.
Source ledger
Every hard claim in this article maps to one of the official pages below. The ledger is also the recommended appendix format for the consultant handoff itself.
Workload and cost framing
Health Canada publishes regulator fees, not your internal review effort. The table below separates the official fee surfaces from an operational estimate for the public-source collection pass.
| Layer | What the source says | Operational meaning |
|---|---|---|
| Filing fees | Official 2026 Health Canada review fees: C$643 (Class II), C$14,163 (Class III), C$30,713 (Class IV). | Do not budget with a single generic "Canada filing fee" number. Keep the class assumption visible and provisional. |
| Ongoing fee | Official 2026 right-to-sell fee: C$460 annually for licensed or authorized Class II, III, and IV devices. | Budget owners should track both one-time filing cost and annual post-licence cost. |
| Public-source prep workload | Inference from the workflow above, not a Health Canada claim. | Expect roughly a focused half day to two working days to collect, verify, and organize the public-source handoff if the product definition already exists. More if intended purpose, labelling, or comparator logic is still unstable. |
What TrueMedDevice prepares and what it does not decide
What we prepare
- Official-source product brief and intended-purpose summary.
- Candidate class and application-type notes with citations.
- REP setup checklist and handoff-ready contact list.
- MDALL similar-device table and safety-history scan.
- Fee snapshot, source ledger, and evidence-gap sheet.
What remains with qualified review
- Health Canada class and submission strategy.
- Whether an MDL, MDEL, amendment, or other route applies.
- Whether evidence is sufficient for filing.
- Any quality-system, legal, safety, or compliance conclusion.
- Any final licence, inspection, or enforcement outcome.
This is not regulatory, legal, or compliance advice. TrueMedDevice does not determine device class, MDL/MDEL eligibility, licence outcome, compliance, safety, or effectiveness. We prepare a source-backed Health Canada / MDALL / public-source evidence pack so qualified RA/QA professionals or regulatory consultants can review and decide.
Final device class and licence outcome remain with qualified RA/QA professionals, consultants, and Health Canada.
Frequently asked questions
If my device looks Class II from MDALL examples, can I treat that as the final class?
No. Public MDALL comparators can create candidate class clues, but they do not determine your final Health Canada class. Final class, application strategy, and licence outcome remain with qualified RA/QA professionals, consultants, and Health Canada.
What is the minimum package I should have before paying a consultant?
At minimum, bring a written intended-purpose statement, candidate class clues with source notes, candidate application-type notes, a draft similar-device table from MDALL, current fee references, and a list of evidence gaps by class. That lets the consultant spend time on judgment rather than basic source collection.
Does a Class II application need the same evidence package as Class III or IV?
No. Health Canada's current guidance says Class II, private-label, and fax-back applications use a more limited subset of the International Medical Device Regulators Forum table-of-contents structure, while Class III and IV applications require a more comprehensive pre-market review package.
Does TrueMedDevice decide whether I need a Medical Device Licence or a Medical Device Establishment Licence?
No. TrueMedDevice does not determine Health Canada class, Medical Device Licence applicability, Medical Device Establishment Licence applicability, submission pathway, licence outcome, compliance status, safety, effectiveness, inspection outcome, or legal obligations. We organize source-backed evidence so qualified RA/QA professionals or consultants can review and decide.
Why include the annual right-to-sell fee in the handoff package?
Because budgeting questions often appear before the consultant call. Health Canada publishes both application review fees and an annual right-to-sell fee for licensed or authorized Class II, III, and IV devices. Keeping both in the handoff pack prevents a false budget picture built only on filing fees.
Want this handoff package built on your device?
We can prepare the Canada-side evidence pack, source ledger, and consultant handoff notes for one product family. Start with the lightest next step that fits your week.
Review support only. We do not provide regulatory, legal, or compliance decisions. Final RA/QA, consultant, and manufacturer decisions remain with qualified reviewers.